@article{1941db9690ed45b499ca14ed1ef48895,
title = "Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstr{\"o}m Macroglobulinemia",
author = "Ghobrial, \{Irene M.\} and Fangxin Hong and Swaminathan Padmanabhan and Ashraf Badros and Meghan Rourke and Renee Leduc and Stacey Chuma and Janet Kunsman and Diane Warren and Brianna Harris and Amy Sam and Anderson, \{Kenneth C.\} and Richardson, \{Paul G.\} and Treon, \{Steven P.\} and Edie Weller and Jeffrey Matous",
note = "Purpose This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenstr{\"o}m macroglobulinemia (WM). Patients and methods Patients who had at least one previous therapy were eligible. All patients received bortezomib intravenously weekly at 1.6 mg/m(2) on days 1, 8, and 15, every 28 days for six cycles and rituximab 375 mg/m(2) weekly on cycles 1 and 4.",
year = "2010",
month = mar,
day = "10",
doi = "10.1200/JCO.2009.25.3237",
language = "American English",
volume = "28",
journal = "Journal of Clinical Oncology",
number = "8",
}